Notch signalling is one of the key pathways in metazoans that regulate cell fate decisions in several systems, including the haematopoietic system.^[@bib1],\ [@bib2]^ In humans, there are four Notch single-pass transmembrane receptors (Notch1--4) and five transmembrane Notch ligands (Delta-like 1/2/3 and Jagged 1/2).^[@bib3],\ [@bib4]^ Notch receptors on maturation in the secretary pathway are presented on the cell surface where they interact with their ligands, leading to two successive cleavage of the Notch receptor by a disintegrin and metalloproteinase family metalloproteases followed by *γ*-secretase, resulting in the production of Notch1 intracellular domain (NICD), which then enters the nucleus.^[@bib5]^ In the nucleus, NICD interacts with the DNA-binding protein recombinant signal-binding protein for immunoglobulin-*κ*J region (RBP-J*κ*; also called CSL). NICD thus displaces the co-repressor from the RBP-J*κ* complex and converts the RBP-J*κ* complex into a transcriptional activator that includes other co activators like mastermind-like protein-1, p300 or p300/CBP-associated factor. Some of the known transcriptional targets of Notch pathway include members of the basic helix-loop-helix Hairy enhancer of split (Hes) factors, Hes-related repressor protein, GATA-3 and Deltex.^[@bib6]^

In the haematopoietic system, Notch signalling has been known to be important for the proper development of the lymphoid compartment; Notch1, in particular, is known to be crucial for T-cell specification over B-cell lineage,^[@bib7]^ whereas Notch2 is known to be required for B-cell development.^[@bib8]^ Moreover, Notch mutations are common in T-cell acute lymphoblastic leukaemia. However, the role of Notch in the myeloid compartment is ambiguous with reports suggesting that Notch1 signalling enhances megakaryocyte differentiation,^[@bib9],\ [@bib10],\ [@bib11],\ [@bib12]^ whereas others indicating the opposite.^[@bib13],\ [@bib14],\ [@bib15]^ Notch pathway activates Akt pathway,^[@bib16],\ [@bib17]^ and reports have also shown the requirement of Akt signalling during megakaryopoiesis.^[@bib18],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^ Recently, it has been shown that during murine megakaryopoiesis, Notch signalling elevates Akt phosphorylation.^[@bib11]^ Whether Notch induces megakaryopoiesis in an Akt-dependent fashion in the context of human haematopoiesis remains to be seen.

Enhancer of zeste homolog-2 (EZH2) is one of the Polycomb group of proteins that functions as a part of chromatin remodelling complex known as Polycomb repressor complex (PRC). EZH2 trimethylates Histones on lysine residues, specifically H3K27, resulting in the subsequent repression by chromatin compaction.^[@bib23]^ EZH2 has been shown to be essential for B-cell development^[@bib24]^ and has been found to be upregulated in proliferating mantle cell lymphoma.^[@bib25]^ Besides interacting with its other PRC2 partners, EZH2 localizes in the cytoplasmic compartment of T cells where it interacts with vav1, thereby regulating T-cell-receptor-mediated signalling.^[@bib26]^ Interestingly, recent reports have suggested a plausible role for EZH2 in myeloid lineage.^[@bib27],\ [@bib28],\ [@bib29]^

Our present study shows that Notch1-induced early megakaryopoiesis is Akt-dependent. During this process, the expression of EZH2 was upregulated in the cytoplasmic compartment where it interacts with a novel interactor -- LIM domain kinase-1 (LIMK1). This reduced Ser3 phosphorylation of cofilin, thereby increasing cofilin activity and hence lowering filamentous actin content within these cells. Notch1 thus not only mediates early megakaryopoiesis but also prepares these cells for the subsequent morphological changes.

Results
=======

Notch1-induced early megakaryopoiesis is Akt-dependent
------------------------------------------------------

To investigate the effect of activated Notch1 pathway on the megakaryocytic lineage, NICD was transfected into K562 and HEL cells. In both these cell lines, NICD caused an upregulation of two megakaryocyte markers -- CD61 and CD42b markers ([Figure 1a](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). Gamma secretase inhibitor (GSI) was used to reduce the intracellular NICD levels in HEL and K562 cells, which resulted in reduced CD42b expression ([Figure 1b](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). As Notch pathway is known to activate the Akt pathway,^[@bib16]^ we looked into the Akt phosphorylation status. We observed an increase in Akt phosphorylation upon NICD transfection in K562 and HEL cells ([Figure 1c](#fig1){ref-type="fig"}). Further, GSI-treated K562 and HEL cells showed a decrease in Akt phosphorylation ([Figure 1d](#fig1){ref-type="fig"}). To understand the importance of Akt in megakaryocytic differentiation, a constitutively active form of Akt (myristoylated, myr-Akt) was transfected into K562 and HEL cells. In both these cell lines, myr-Akt caused increased expression of CD61 and CD42b ([Figure 1e](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). In addition, inhibition of Akt by the PI3K/Akt inhibitor LY294002 also reduced CD42b levels in K562 cells transfected with NICD (mean fluorescence intensity with respect to K562 NICD is 0.83±0.08, *P*\<0.001, *n*=3; [Figure 1f](#fig1){ref-type="fig"}). Further, K562 NICD had a CD61 content resembling that of K562 within the first 2 h of 12-*O*-tetradecanoylphorbol 13-acetate (TPA) treatment ([Figure 1g](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Thus, NICD-induced early megakaryopoiesis is mediated by the Akt pathway.

Changes in transcription factor brought on by NICD
--------------------------------------------------

The expression of some key genes and transcription factors required for erythroid--megakaryocytic differentiation was also analysed in K562 cells transfected with NICD. PU.1, EKLF and myb were downregulated in the presence of NICD, whereas integrin-*α*V and integrin-*β*3 was upregulated. Expression of megakaryocyte specifying transcription factors like GATA-1, FOG1, Fli1 and NF-E2 decreased on NICD transfection reminiscent of a similar reduction after TPA treatment ([Figure 2a](#fig2){ref-type="fig"}). Further, treatment with TPA for different time points showed an initial decrease in the expression of GATA2 followed by a sustained increase ([Figure 2b](#fig2){ref-type="fig"}). As GATA-2 can mediate megakaryopoiesis in the absence of GATA-1,^[@bib30]^ our results indicate that at least in K562 NICD system, GATA-2 overrides the effect of GATA-1. Our data also shows similarity in the regulation of NICD-induced *Hes*/*Hey* genes between K562 cells transfected with NICD and K562 cells treated with TPA ([Figure 2c](#fig2){ref-type="fig"}). Together, these data point towards an early megakaryocytic-lineage specification by NICD. To verify the biological relevance of Notch signalling during megakaryopoiesis, CD34^+^ haematopoietic stem and progenitor cells were isolated from human cord blood samples and were cultured in the presence of a cocktail of cytokines, and analysed for the expression of CD61 and CD42b ([Figure 2d](#fig2){ref-type="fig"}). The expression of the Notch pathway genes was analysed at day 10 of sorted CD61^+^CD42b^+^ cells compared with day 0 of megakaryocyte culture. Results show an increase in the mRNA expression of Jag1. Expression of Jag2 remained undetected at day 0, whereas its expression was observed at day 10 in four independent samples. Expression of megakaryocytic genes showed an increase at day 10 compared with day 0, whereas transcription of EKLF, an erythroid lineage-specific transcription factor decreased significantly ([Figure 2e](#fig2){ref-type="fig"}). Together, the above data not only demonstrates the importance of NICD in mediating megakaryopoiesis, but also shows a correlation between Notch pathway and megakaryopoiesis during *in-vitro* differentiation of CD34^+^ cells into megakaryocyte lineage.

NICD increases cytoplasmic EZH2 levels during early megakaryopoiesis
--------------------------------------------------------------------

In light of recent reports linking EZH2 to myeloid lineage, we investigated the role of EZH2 in megakaryopoiesis. NICD-transfected K562 cells were found to have elevated EZH2 levels. Surprisingly, no significant change in histone-3 trimethylated on lysine 27 (H3K27me3) levels was detected ([Figure 3a](#fig3){ref-type="fig"}). The nuclear and cytoplasmic distribution of the protein was therefore analysed. Nuclear expression of EZH2 was found to be fairly unchanged, whereas cytoplasmic levels increased with NICD expression ([Figure 3b](#fig3){ref-type="fig"}). As NICD increased Akt phosphorylation, we checked whether expression of myr-Akt could mimic this effect of NICD, and found a similar upregulation of EZH2 in the absence of NICD ([Figure 3c](#fig3){ref-type="fig"}). Also, blocking Akt phosphorylation in K562 NICD cells with LY294002 caused a decrease in the transcript levels ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}) as well as in the cytoplasmic EZH2 levels ([Figure 3d](#fig3){ref-type="fig"}). The effect of Notch on cytoplasmic EZH2 levels was also verified in Jurkat cells as Notch pathway is activated in these cells and previous report had also indicated that T-cell receptor signalling is affected by cytoplasmic EZH2.^[@bib26]^ Our data shows that both phosphorylation of Akt and cytoplasmic EZH2 levels decreased upon GSI treatment of Jurkat cells ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}). In K562 cells, EZH2 accumulates in the cytoplasm during early time points of TPA treatment ([Figure 3e](#fig3){ref-type="fig"}). To investigate the role of Akt in megakaryopoiesis, phosphorylated Akt levels were checked at different time points of TPA treatment of K562 cells. Results show an increase in phosphorylated Akt during early time points of differentiation, indicating that upregulation of EZH2 is brought about by NICD-induced Akt phosphorylation. A similar expression of EZH2 was seen with HEL cells treated with TPA for different time points and HEL cells transfected with NICD ([Figure 3f](#fig3){ref-type="fig"}). Thus, early megakaryocyte specification by NICD mediated by phosphorylated Akt involves the upregulation of EZH2, which accumulates more in the cytoplasm of these cells. EZH2 levels were also checked in *in-vitro* megakaryocyte cultures at day 5 (CD61^+^CD42b^−^) and day 10 (CD61^+^CD42b^+^) of sorted cells. The transcript levels of EZH2 were found to be higher compared with day 0 of cultures ([Figure 3g](#fig3){ref-type="fig"}). Also, EZH2 content measured in the bone marrow mononuclear cells stained for two megakaryocytic markers CD61 and CD42b showed that CD61^+^ CD42b^−^ population had lower EZH2 content than CD61^+^CD42b^+^ population ([Figure 3h](#fig3){ref-type="fig"}), again indicating the requirement of EZH2 during megakaryopoiesis. Thus, we have for the first time illustrated the importance of NICD in upregulation of cytoplasmic EZH2. We have also shown that this effect is seen during early stages of megakaryocyte differentiation.

Novel cytoplasmic partners of EZH2
----------------------------------

EZH2 is known to form a functional methyl transferase complex with Eed and Suz12 in the cytoplasm. The only known non-PRC protein that interacts with EZH2 in the cytoplasm is vav1.^[@bib31]^ The expression of vav1 was found to decrease after NICD transfection ([Figure 4a](#fig4){ref-type="fig"}). To elucidate the function of EZH2, we attempted to find the other cytoplasmic partners of EZH2 by co-immunoprecipitation (Co-IP) of EZH2 followed by matrix-assisted laser desorption ionization (MALDI) MS/MS-based identification of the immunoprecipitates. Five proteins were thus identified -- PDIA1, LIMK1, heat-shock protein 90*β*, tubulin-*α*6 variant and gamma actin. Details of the MALDI MS/MS analysis are given in the [Supplementary Information S2](#sup1){ref-type="supplementary-material"}. The interaction of cytoplasmic EZH2 with LIMK1 and protein disulphide isomerase (PDI) was confirmed by Co-IP experiment in which antibody against LIMK1/PDI was used to pull down EZH2 ([Figure 4b](#fig4){ref-type="fig"}). The interactions were further confirmed by reverse immunoprecipitation ([Supplementary Figure S1C and D](#sup1){ref-type="supplementary-material"}). In addition, immunocytochemisty confirmed that EZH2 and LIMK1 colocalized in the cytoplasm of NICD-transfected K562 cells ([Figure 4c](#fig4){ref-type="fig"}). Thus, two new cytoplasmic interactors of EZH2 were identified -- LIMK1 and PDIA1.

Cytoplasmic EZH2 induces changes in filamentous actin content
-------------------------------------------------------------

To understand the function of EZH2 in the cytoplasmic compartment of these cells, the interactors were further probed. In K562 cells transfected with NICD, which show an early megakaryocytic propensity, PDIA1 itself was upregulated. LIMK1 levels however remain unchanged ([Supplementary Figure S1E](#sup1){ref-type="supplementary-material"}). As LIMK1 and vav1 are both involved in the regulation of actin dynamics, we looked into how NICD affects the other factors in this process. The Rho and Rac GTPases showed altered levels in the presence of NICD, whereas cdc42 levels remain unchanged ([Figure 5a](#fig5){ref-type="fig"}). LIMK1 is known to function immediately upstream of the actin polymer-severing protein cofilin. It phosphorylates cofilin, thereby rendering it inactive.^[@bib32]^ Phosphorylation of cofilin decreased upon NICD activation ([Figure 5b](#fig5){ref-type="fig"}). Further, total filamentous actin content decreased marginally in NICD-transfected cells (mean fluorescence intensity with respect to K562 is 0.84±0.015, *n*=3; [Figure 5c](#fig5){ref-type="fig"}). To address the question whether EZH2 has any role in inducing changes in the actin cytoskeleton structure, EZH2ΔNLS was transfected into K562 cells. This caused a decrease in the phosphorylated cofilin levels ([Figure 5d](#fig5){ref-type="fig"}). Also, siRNA against EZH2 showed an increase in phosphorylated cofilin levels ([Figure 5e](#fig5){ref-type="fig"}). Together, these results indicate a role for EZH2 in modulating the filamentous actin content within these cells through regulation of cofilin phosphorylation. As Akt pathway mediated the cytoplasmic localization of EZH2, LY294002 was used to inhibit Akt pathway to see its effect on actin-filament-severing proteins. We found that phosphorylated cofilin levels increased upon treatment with LY294002 ([Figure 5f](#fig5){ref-type="fig"}). Similar effects were seen with F-actin content in K562 transfected with NICD and K562 NICD-transfected cells treated with LY294002, wherein a decrease in F-actin content brought about by NICD could be reversed with LY294002 treatment (mean fluorescence intensity compared with K562 NICD 1.16±0.015, *n*=3; [Figure 5g](#fig5){ref-type="fig"}). Again, myr-Akt caused decreased phosphorylation of cofilin ([Figure 5h](#fig5){ref-type="fig"}). Thus, NICD-mediated increase in cytoplasmic EZH2 levels results in decreased filamentous actin content within early megakaryocytes.

Discussion
==========

The role of Notch pathway during megakaryocyte differentiation has been greatly studied, but there are differences in terms of the results, with reports suggesting that Notch pathway enhances megakaryopoiesis,^[@bib9],\ [@bib10],\ [@bib11],\ [@bib12]^ whereas others suggesting the reverse.^[@bib13],\ [@bib14],\ [@bib15]^ Despite these differences, the reports clearly indicate that Notch pathway is a crucial determinant during megakaryopoiesis in both human and murine systems. In this study, we have addressed the question of Notch-induced megakaryopoiesis and its impact on the cellular actin network.

As observed by the surface marker expression of CD61 and CD42b, NICD was found to induce megakaryocytic differentiation of K562 and HEL cells. In addition, during *in-vitro* megakaryocyte differentiation from cord blood CD34^+^ cells, Notch1 pathway genes such as *Jag1* and *Jag2* were upregulated in conjunction with megakaryocyte specifying transcription factors. It is known that GATA-1, Fog1, Fli1 and NF-E2 are required for megakaryocytic differentiation. GATA-1 is dispensable for the onset of megakaryopoiesis, but is required for the maturation of megakaryocytes.^[@bib33],\ [@bib34]^ Similarly, mice lacking p45NF-E2 produced megakaryocytes that showed defective platelet production, although other parameters of megakaryocyte maturation like endomitosis and expression of GPIIb occurred.^[@bib35]^ Also, loss of Fli1 in adult mice resulted in mild thrombocytopenia associated with a marked reduction of megakaryocytic progenitors and maturation defect of megakaryocytes present in bone marrow.^[@bib36]^ Thus, although these transcription factors are essential for proper megakaryocyte development, their absence does not lead to a complete ablation of megakaryocytes. The decrease in the mRNA levels of these transcription factors in NICD-induced K562 cells as well as TPA-treated K562 cells indicates that these proteins are already present in K562 cells in amounts sufficient to induce changes necessary for megakaryopoiesis (GATA-1 protein levels in NICD-transfected K562 cells shown in [Supplementary Figure S1G](#sup1){ref-type="supplementary-material"}). Further, the mRNA levels of these transcription factors increases during *in-vitro* megakaryocyte production from cultured CD34^+^ cells as shown in [Figure 2e](#fig2){ref-type="fig"}. Interestingly, loss of GATA-1, FOG1 and NF-E2 has also been shown to affect erythropoiesis.^[@bib37],\ [@bib38],\ [@bib39]^ A bipotent cell line such as K562, which can differentiate either towards erythroid or megakaryocyte lineage, expresses all these transcription factors as shown by qRT-PCR data ([Figure 2a](#fig2){ref-type="fig"}). In such cells, downregulation of these transcription factors may be helpful in induction of megakaryopoiesis in preference to erythropoiesis. It is known that GATA-2 can mediate megakaryopoiesis in the absence of GATA-1.^[@bib35]^ Our data shows that GATA-2 expression was upregulated in TPA-treated K562 cells. Further, treatment with TPA for different time points showed an initial decrease in the expression of GATA-2 followed by a sustained increase. These results are in agreement with previous reports^[@bib36],\ [@bib37]^ in which overexpression of GATA-2 promoted megakaryocytic differentiation at the expense of erythroid differentiation. Also, integrin-*α*V and integrin-*β*3 transcript level was upregulated. Interestingly, integrin-*β*3 is also a known surface marker of megakaryocytes and platelet, also called CD61, and has been widely used to detect early maturation stages of megakaryocytes and in this study integrin-*β*3 expression level was used as a marker for characterizing megakaryocytic differentiation. Thus, the CD61 levels and megakaryocyte-specific transcription factor levels point towards an early megakaryocyte specification by NICD. This process was found to be Akt-dependent. In fact, dependence of megakaryopoiesis on Akt was previously demonstrated in murine megakaryopoiesis.^[@bib11]^ Our data indicates that Akt is crucial for Notch-dependent megakaryopoiesis, as inhibition of Akt in NICD-transduced cells leads to lower megakaryocyte-specific markers CD61 and CD42b.

The early indications that EZH2 could be involved in myeloid lineage specification came from the genomic location of EZH2 within the 7q35 locus also known for its involvement in malignant myeloid disorders.^[@bib40]^ Later reports had indicated a possible role for EZH2 in megakaryocyte development and maturation. In particular, the expression of EZH2 was found to increase in the newly produced megakaryocytic lineage cells after conditional eradication of CD41^+^ cells.^[@bib27]^ Further, patients with myelodysplastic syndrome, who usually express a dysplasia of erythroid/megakaryocytic compartment, were found to harbour somatic mutations of *EZH2* gene.^[@bib28]^ A recent report also points out the importance of EZH2, wherein conditional deletion of EZH2 in mice fetal livers reduced the numbers of myeloid progenitors, including megakaryocyte erythocyte progenitors.^[@bib29]^ We thus investigated the role of EZH2 in megakaryopoiesis. Our results show for the first time that EZH2 is upregulated during the early megakaryocytic differentiation event and this is accomplished by the Notch1 pathway in an Akt-dependent manner. EZH2 is upregulated in the NICD-transfected K562 and HEL cells. Moreover, EZH2 expression increases during early time points of TPA-induced differentiation of both K562 and HEL cells. This correlates with the levels of phosphorylated Akt that also shows similar increase during TPA-induced differentiation. EZH2 was previously shown to localize in the cytoplasmic compartment of cells.^[@bib26]^ Here we show that EZH2 is found in the cytoplasm of K562 cells and it is this cytoplasmic EZH2, which increases during the first hour of TPA-induced K562 differentiation. Moreover, cytoplasmic EZH2 levels increased upon NICD transfection of K562 cells, whereas the nuclear levels of the protein remained unchanged, a result well corroborated by the level of trimethylation of histone3 (H3K27me3). These data not only point towards an early event of megakaryocytic differentiation brought on by NICD, but also highlight the importance of Akt signalling in increasing the cytoplasmic EZH2 levels. Further, during *in-vitro* megakaryopoiesis from CD34^+^ cells, EZH2 transcript levels were found to increase. Such an increase was also seen when bone marrow cells were analysed for the expression of CD61 and CD42b, and then compared for the expression of EZH2.

EZH2 is known to form a functional complex with its PRC2 partners Eed and Suz12 in the cytoplasm. Previous reports had shown that EZH2 could interact with vav1 and modulate T-cell receptor signalling.^[@bib26]^ In this study, we tried to determine the other cytoplasmic interactors of EZH2. PDIA1 and LIMK1 emerged as the two new protein interactors. PDI, a known endoplasmic reticulum marker, functions as a protein disulphide isomerase, and hence, it derives its name. It has long been known to localize in the cytoplasm of megakaryocytes. In platelets, PDI is primarily found on the plasma membrane.^[@bib41]^ Also, PDI is known to facilitate platelet aggregation.^[@bib42]^ In our system, PDI was found to be upregulated in NICD-transfected K562 cells, which themselves acquire a megakaryocyte specification, and thus, an increase in PDI content in Notch-transfected K562 cells only further points to the role of Notch in facilitating megakaryocyte lineage. LIMK1 is known to function immediate upstream of the actin polymer-severing protein cofilin. It phosphorylates cofilin, thereby rendering it inactive. Here we propose a mechanism by which NICD increases the cytoplasmic levels of EZH2, which then interacts with LIMK1 resulting in reduced Ser3 phosphorylation of cofilin, which prepares these cells for subsequent changes in cell shape and size necessary for megakaryocyte formation. Together with the ability to increase the cytoplasmic EZH2 levels, NICD also causes changes in the levels of Rho/Rac GTPases that have a crucial role in cell morphology. Of particular interest is the nature of regulation of these small Rho GTPases -- RhoA and Rac levels declined, whereas cdc42 levels remained unchanged with NICD induction. Although previous reports have implicated EZH2 in prostate cancer metastasis,^[@bib43]^ this is the first attempt at understanding the molecular factors involved in EZH2-mediated remodelling of actin cytoskeleton. This study revealed that NICD-induced early megakaryocytic differentiation was accompanied by an increase in the cytoplasmic levels of EZH2, which resulted in increased cofilin activity and hence altered filamentous actin levels within these cells. Although we have produced evidence for an Akt-dependent increase in cytoplasmic EZH2 levels, it would however be interesting to investigate how activation of the Akt signalling leads to increased cytoplasmic EZH2 levels. Although, Akt is known to phosphorylate EZH2 on serine 21,^[@bib44]^ it remains to be seen whether the cytoplasmic localization of the protein is directly controlled by Akt. In conclusion, this study shows that Notch1 pathway leads to Akt-dependent early megakaryopoiesis and is accompanied by increased cytoplasmic EZH2 levels. Finally, we show how cytoplasmic EZH2 changes the filamentous actin content within early megakaryocytes by interacting with LIMK1.

Materials and Methods
=====================

Culture of CD34^+^ cells and cell lines
---------------------------------------

K562 and HEL cells were cultured in RPMI1640 (Gibco, Carlsbad, CA, USA) with 10% FBS (Gibco). For isolation of CD34^+^ cells, mononuclear cells were isolated from cord blood using Percoll (GE Amersham, Buckinghamshire, UK) and CD34^+^ cells were enriched by magnetic separation (Miltenyi Biotech, Bergisch Gladbach, Germany). Purity of the isolated cells was determined using anti-CD34 antibody (BD Biosciences, San Jose, CA, USA). Megakaryocyte culture was initiated using freshly isolated CD34^+^ cells using the protocol.^[@bib45]^ Megakaryocyte population was sorted at day 5 (CD61^+^CD42b^−^) and day 10 (CD61^+^CD42b^+^) of *in-vitro* culture in a FACS AriaII system (BD Biosciences). All clinical samples were collected under consent, following strict institutional ethical guidelines.

Plasmids constructs
-------------------

The expression vector for the activated form of Notch1 pCDNA-Myc-HisN1IC (NICD) was gifted by J Aster (Harvard Medical School). CMV(myc)3EZH2 was a kind gift from T Jenuwein (Max Planck Institute of Immunology and Epigenetics). EZH2ΔNLS was subcloned into RFP vector using the primers 5′-GATTAGTCGACGAATGGAAACAGCGAAGGA-3′ and 5′-GGTCTGGATCCAAGGCAGCTGTTTCAGAGGA-3′.

RNA extraction and real-time PCR
--------------------------------

RNA was isolated using Trizol (Roche, Mannheim, Gemany). The expression level of genes was assessed by quantitative RT-PCR using SYBR Green core PCR reagents (Applied Biosystems, Carlsbad, CA, USA). Hypoxanthine phosphoribosyl transferase-1 (HPRT1) was used to normalize the expression of the genes. The reactions were carried out in 7500 Sequence Detection Systems (Applied Biosystems). Details of the primer sequence are given in the [Supplementary Methods](#sup1){ref-type="supplementary-material"}.

Reagents and antibodies
-----------------------

Antibodies against EZH2, LIMK1, PDI, vav1, Rac1/2/3, cdc42, cofilin, phospho-cofilin, Akt and phospho Akt were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibody against RhoA was purchased from Abcam (Cambridge, MA, USA). PE-conjugated CD235a was obtained from Serotec (Kidlington, UK), whereas APC-conjugated CD42b, PE-conjugated CD61 and PE-conjugated CD34 was purchased from BD Biosciences. Flow cytometric analysis was performed on a BD FACS Calibur platform. EZH2 siRNA was obtained from Sigma (St. Louis, MO, USA) using the sequence specified in Chen *et al.*^[@bib46]^ TPA (Sigma) was used at 32 nM concentration for 24/48 h.

Co-IP and western blotting
--------------------------

Nuclear and cytoplasmic extracts were prepared using NE-PER Nuclear and Cytoplasmic extraction reagents Pierce (Rockford, IL, USA). Four hundred microgram of K562 NICD-transfected cytoplasmic extract was incubated with 2 *μ*l of EZH2 antibody at 4 °C for 2 h. Twenty microlitre of protein A/G agarose bead (Santa Cruz, Santa Cruz, CA, USA) was added and incubated overnight at 4 °C. The immunoprecipitate was obtained by centrifugation at 5000 r.p.m. for 5 min. The immunoprecipitate was washed thrice and the remaining immunoprecipitate was resolved on 12% SDS-PAGE. For protein identification, the gel was stained with Blue Silver stain, and the bands obtained were cut for protein identification. For western blotting, cells were harvested and lysed in cold RIPA buffer. Equal amounts of protein was run on SDS-PAGE and blotted on PVDF membrane (GE Amersham). Following incubation with primary and HRP-conjugated secondary antibodies, the blots were developed using enhanced chemiluminescent substrate (Pierce).

MALDI-based protein annotation
------------------------------

The bands obtained were excised, digested with trypsin (Promega, Madison, WI, USA) and analysed using Applied Biosystems AB 4700 MALDI TOF/TOF mass spectrometer following methodologies by Bienvenut *et al.*^[@bib47]^ and Bhattacharya *et al.*^[@bib48]^ Briefly, trypsin-digested peptides were spotted with *α*-cyano-4-hydroxycinnamic acid matrix by the sandwich method and mass spectrometry (MS) spectra collected in the positive reflector mode. MS/MS spectra were obtained for the corresponding peptides from the 12 most intense peptides seen in MS spectra. The peak list prepared from raw MS and MS/MS data using GPS explorer V3.6 (Applied Biosystems) was searched against human MSDB database using MASCOT (version 2.0.05; Matrixscience, London, UK) server, and the probability-based MOWSE score was considered to determine hits.

Confocal imaging
----------------

Cells were washed thrice in phosphate-buffered saline (PBS). The cells were fixed for 30 min in 4% formaldehyde (Merck, Whitehouse Station, NJ, USA). Cells were washed thrice with PBS and permeabilized in 0.2% TritonX100 (Sigma) with 10% FBS. After 1 h, cells were washed thrice with PBS and incubated with primary antibodies overnight at 4 °C. Cells were washed again and incubated in secondary tagged antibody (Alexa fluor 488 and Alexa fluor 633, Invitrogen, Carlsbad, CA, USA) for 2 h. After washing in PBS, cells were visualized in the confocal mode in a Carl Zeiss LSM 510 Meta microscope (Jena, Germany).

Statistical analysis
--------------------

Statistical significance of the difference between the different conditions was assessed using a two-tailed Student\'s *t*-test.
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![NICD induces early megakaryocytic differentiation. (**a**) Flow cytometric analysis of CD61 and CD42b markers in K562, K562 NICD, HEL and HEL NICD. (**b**) Flow cytometric analysis of CD61 and CD42b markers in K562, HEL with/without GSI treatment. (**c**) Western blot of whole-cell lysates of K562, K562 NICD, HEL and HEL NICD showing the relative expression of phospho-Akt and Akt. (**d**) Phospho-Akt and Akt expression in GSI-treated K562 and HEL cells. For K562 cells, 0.5 and 1 *μ*M GSI was used, whereas for HEL cells, 1 *μ*M GSI was used. Densitometric analysis of the blots is provided in the [Supplementary Information S3](#sup1){ref-type="supplementary-material"}. (**e**) Flow cytometric analysis of CD61 and CD42b in K562, K562 myr-Akt, HEL and HEL myr-Akt. (**f**) Flow cytometric analysis of CD42b-stained K562 NICD cells and it\'s LY294002 (20 *μ*M)-treated counterpart. (**g**) Mean fluorescence intensity of CD61-stained K562, K562 NICD and K562 treated with TPA for different time points](cddis2012119f1){#fig1}

![NICD induced change in transcription factors. (**a**) Relative gene expression in K562 transfected with NICD and K562 treated with TPA compared with K562 cells. The mRNA expression of each gene was normalized to the expression of HPRT1 mRNA. Data represents the mean±s.e.m of four independent experiments (*P*\<0.001, *n*=4). (**b**) Relative gene expression of GATA-2 at different time points of TPA treatment as seen by qRT-PCR. Data represents the mean±s.e.m of three independent experiments (*P*\<0.002, *n*=3). (**c**) Relative gene expression where data represents the mean±s.e.m of three independent experiments (*P*\<0.002, *n*=3). (**d**) CD34^+^ cells isolated from cord blood induced into megakaryocytic lineage. CD61^+^CD42b^−^ and CD61^+^CD42b^+^ populations were sorted at the end of 5 days and 10 days of megakaryocytic culture. (**e**) Differentiation was assessed with surface markers CD61 and CD42b. qRT-PCR levels of Notch1 pathway genes and megakaryocyte-specific transcription factors at day 10 (CD61^+^CD42b^−^) megakaryocyte cultures compared with day 0 cultures. Data represents mean±s.e.m of three independent experiments (*P*\<0.005)](cddis2012119f2){#fig2}

![NICD induces Akt-dependent upregulation of cytoplasmic EZH2. (**a**) Western blot of whole-cell lysate of K562 and K562 NICD showing the expression of EZH2 and H3K27me3 (histone-3 trimethylated on lysine 27). (**b**) EZH2 expression in the nuclear and cytoplasmic fractions of K562 and K562 NICD. (**c**) Western blot showing the expression of EZH2 in K562 and K562 myr-Akt. (**d**) EZH2 expression in the nuclear and cytoplasmic fractions of K562 cells treated with the mentioned concentrations of LY294002 with/without NICD transfection. (**e**) EZH2 expression in the cytoplasmic compartments of K562 NICD and K562 at different time points of TPA treatment. Lower panel shows phosphorylation levels of Akt at different time points of TPA treatment. (**f**) EZH2 expression in the whole-cell lysates of HEL at different time points of TPA treatment. Lower panel shows the expression of EZH2 in NICD-trasfected HEL cells. Densitometric analysis of the blots is provided in the [Supplementary Information S3](#sup1){ref-type="supplementary-material"}. (**g**) qRT-PCR of EZH2 levels in day 5 and day 10 of megakaryocyte cultures compared with day 0 cultures. Data represents mean±s.e.m of three independent experiments (*P*\<0.001). (**h**) Mononuclear cells isolated from bone marrow aspirates and stained with CD61 and CD42b to identify megakaryocyte population and anti-EZH2 antibody. The level of EZH2 was determined from CD61^+^CD42b^−^ (R1)- and CD61^+^CD42b^+^ (R2)-gated cells](cddis2012119f3){#fig3}

![Cytoplasmic interactors of EZH2. (**a**) Western blot of whole-cell lysates showing the expression of vav1 in NICD-transfected K562 cells. Densitometric analysis of the blots is provided in the [Supplementary Information S3](#sup1){ref-type="supplementary-material"}. (**b**) Co-IP results in which antibody against LIMK1 was used to pull down LIMK1--protein complex and probed for EZH2, and antibody against PDI was used to pull down PDI--protein complex and probed for EZH2. (**c**) Immunocytochemistry of K562 NICD cells. Confocal images of LIMK1-, EZH2- and DAPI-stained cells were analysed for colocalization of LIMK1 and EZH2. (*R*=0.57, s.e.m.±0.047, *P*-value\<0.001)](cddis2012119f4){#fig4}

![Cytoplasmic EZH2 induced changes in filamentous actin content. (**a**) Western blots of whole-cell lysates of K562 and K562 NICD representing changes in Rho/Rac/cdc42 GTPases. (**b**) Western blots of whole-cell lysates of K562 and K562 NICD showing the changes in expression of Ser3 phosphorylated cofilin. (**c**) Filamentous actin content in K562 and K562 NICD cells. (**d**) Western blot of whole-cell lysates of K562, K562 EZH2ΔNLS and K562 NICD analysed for the expression of Ser3-phosphorylated cofilin and cofilin. (**e**) Western blot of whole-cell lysates of K562, K562 NICD and K562 NICD treated with different concentrations of EZH2 siRNA was analysed for the expression of Ser3-phosphorylated cofilin and cofilin. (**f**) Western blots of whole-cells lysates of K562 cells treated with LY294002 with the mentioned concentrations in *μ*M with/without NICD transfection. (**g**) Filamentous actin content in K562 NICD and K562 NICD treated with LY294002. (**h**) Western blots of whole-cell lysates of K562, K562 myr-Akt, HEL and HEL myr-Akt representing changes in phosphorylation of cofilin. Densitometric analysis of the blots is provided in the [Supplementary Information S3](#sup1){ref-type="supplementary-material"}](cddis2012119f5){#fig5}

###### Megakaryocyte-specific marker expression

            **K562**           **HEL**                          
  --------- ------------------ --------------- ---------------- ----------------
  NICD      1.3±0.03\*         1.23±0.02\*     1.55±0.016\*     1.15±0.015\*\*
  GSI       0.97±0.086\*\*\*   0.8±0.047\*\*   1.09±0.016\*\*   0.82±0.03\*\*
  myr-Akt   1.14±0.012\*\*     1.17±0.03\*     1.57±0.08\*      1.62±0.09\*\*

K562 and HEL cells were transfected with NICD and myr-Akt, and fold increase in the expression of CD61 and CD42b was analysed. K562 and HEL cells were subjected to 1 *μ*M GSI treatment and the megakaryocyte marker expression was analysed. Expression of CD61 and CD42b in K562 was taken as 1 and the fold changes of treated/transfected cells were calculated. Mean±s.e.m. of three independent experiments are shown (\**P*\<0.0001, \*\**P*\<0.001, \*\*\**P*\<0.01).

###### CD61 expression in TPA-treated K562 cells

  **K562+32 nM TPA (hours of treatment)**   **Fold change in mean fluorescence intensity with respect to K562**
  ----------------------------------------- ---------------------------------------------------------------------
  0.5                                       1.12±0.015\*
  1                                         1.23±0.014\*
  2                                         1.2±0.01\*
  4                                         1.43±0.018\*\*
  8                                         1.86±0.047\*\*
  24                                        3.59±0.086\*\*

K562 cells were treated with TPA for different time points and fold change in the expression of CD61 was analysed. Expression of CD61 in K562 was taken as 1 and fold changes were calculated with respect to K562. Mean±s.e.m. of three independent experiments are shown (\**P*\<0.005, \*\**P*\<0.001).
